Soft Tissue Sarcoma: Stats and More

What Is Soft Tissue Sarcoma?

Soft tissue sarcoma is cancer that begins in the tissues that connect, support, or surround other structures in the body. These tissues include:

• Muscles
• Fat
• Blood and lymph vessels
• Nerves
• Tendons and ligaments
• Fibrous tissue
• Tissue around joints

A sarcoma may develop almost anywhere, although the arms, legs, abdomen, and retroperitoneumthe area behind the abdominal organsare common locations. Some tumors also arise in the chest, head, neck, or tissues within an organ.

Soft tissue sarcoma should not be confused with carcinoma, the much more common category of cancer that begins in tissues lining organs or body surfaces. Sarcoma starts in connective or supportive tissue and accounts for only about 1% of adult cancers. It represents a larger share of childhood cancers, although pediatric sarcomas often differ biologically from adult disease.

Soft Tissue Sarcoma Statistics in the United States

Estimated cases and deaths in 2026

The American Cancer Society estimates that approximately 13,910 new soft tissue sarcomas will be diagnosed in the United States during 2026. The estimate includes about 7,840 cases in males and 6,070 in females.

About 5,400 deaths are expected, including approximately 2,960 males and 2,440 females. These estimates include adults and children.

Soft tissue cancers represent roughly 0.7% of all new U.S. cancer cases and about 0.9% of cancer deaths. The age-adjusted incidence rate is approximately 3.5 new cases per 100,000 people per year, while the death rate is about 1.3 per 100,000.

Those percentages are small compared with common cancers such as breast, prostate, lung, and colorectal cancer. Unfortunately, rare does not mean harmless. It often means fewer patients are available for clinical trials, fewer community physicians regularly encounter the disease, and individual subtypes may have limited research data.

Overall and stage-based survival rates

SEER data covering people diagnosed from 2016 through 2022 show an overall five-year relative survival rate of approximately 65.7% for soft tissue cancer. Relative survival compares people with cancer to people of the same age and sex in the general population.

Survival changes substantially according to how far the cancer has spread when first diagnosed. Data for diagnoses from 2015 through 2021 show the following five-year relative survival rates:

These figures are useful for understanding broad patterns, but they are not personal expiration dates stamped by an overly dramatic office printer. They do not fully account for tumor grade, subtype, genetic alterations, surgical margins, response to therapy, recurrence pattern, age, or newer treatments introduced after the patients in the database were treated.

Common Types of Soft Tissue Sarcoma

Soft tissue sarcoma is an umbrella term rather than one disease. Common adult subtypes include:

• Undifferentiated pleomorphic sarcoma: Often develops in the arms or legs and contains highly abnormal-looking cells without a clearly identifiable tissue of origin.
• Liposarcoma: Begins in fat cells, frequently in a thigh or behind the abdominal organs.
• Leiomyosarcoma: Develops in smooth muscle, including muscle in the uterus, blood vessels, or abdomen.
• Synovial sarcoma: Often appears near major joints but does not necessarily begin in joint lining.
• Angiosarcoma: Starts in cells lining blood or lymph vessels.
• Malignant peripheral nerve sheath tumor: Develops in tissue surrounding peripheral nerves.
• Rhabdomyosarcoma: A muscle-related sarcoma seen more often in children and adolescents.

Gastrointestinal stromal tumors are also soft tissue tumors, but they have distinctive molecular features and are often discussed separately because their treatment can differ significantly.

Signs and Symptoms to Watch

Soft tissue sarcoma may cause few symptoms while it is small. Soft tissues can stretch around a growing tumor, giving it room to expand without immediately complaining. The body is accommodating like thatsometimes far too accommodating.

A growing lump

A painless lump is the most familiar warning sign. About half of soft tissue sarcomas begin in an arm or leg, and many people notice a mass that enlarges over several weeks or months. It may eventually become painful if it presses on muscles, nerves, or blood vessels.

A new or enlarging lump deserves medical evaluation, particularly when it is deep, firm, difficult to move, painful, or larger than approximately 2 inches. These features do not prove that a mass is cancerous, but they increase the need for appropriate imaging.

Symptoms of an abdominal sarcoma

Roughly four in ten soft tissue sarcomas begin in the abdomen. A tumor deep inside the abdomen can become large before it is visible or easy to feel. Possible symptoms include:

• Persistent or worsening abdominal pain
• A feeling of fullness or abdominal swelling
• Nausea or vomiting
• Unexplained weight loss
• Blood in vomit or stool
• Black, tarry stools caused by gastrointestinal bleeding

Most lumps and digestive symptoms have causes other than sarcoma. The practical message is not to panic over every bump. It is to seek medical evaluation when a symptom is new, persistent, enlarging, or unexplained.

Causes and Risk Factors

For most people diagnosed with soft tissue sarcoma, doctors cannot identify a single cause. The cancer develops after cells acquire DNA changes that allow them to grow abnormally, but why those changes occurred is usually uncertain.

Known risk factors include:

• Previous radiation therapy
• Long-term lymphedema
• Exposure to certain chemicals, including vinyl chloride, arsenic, or thorium dioxide
• Inherited conditions such as Li-Fraumeni syndrome
• Neurofibromatosis type 1
• Hereditary retinoblastoma
• Familial adenomatous polyposis or Gardner syndrome
• Other uncommon hereditary cancer syndromes

Having a risk factor does not mean a person will develop sarcoma. Likewise, having no known risk factors does not provide complete protection. Unlike several common cancers, soft tissue sarcoma has no routine screening test recommended for the general population.

How Soft Tissue Sarcoma Is Diagnosed

Imaging tests

Evaluation usually begins with a physical examination and imaging. Ultrasound may help distinguish a fluid-filled cyst from a solid mass. MRI provides detailed images of tumors in the arms, legs, pelvis, or other soft tissues. CT scans are particularly useful for tumors in the chest or abdomen and for checking whether cancer has reached the lungs.

PET scans may be appropriate in selected situations, although they are not necessary for every patient.

Biopsy and pathology review

A biopsy is required to confirm soft tissue sarcoma. A core needle biopsy commonly removes several narrow samples of tissue for examination. The biopsy route should be planned carefully because it can affect later surgery. Ideally, the surgeon or sarcoma team responsible for definitive treatment should participate in that planning.

A pathologist studies the tissue under a microscope and may use immunohistochemistry, molecular testing, or genetic analysis to identify the subtype. Because some sarcomas resemble benign tumors or other cancers, review by a pathologist experienced in sarcoma can be valuable.

Grade and stage

Tumor grade describes how aggressive the cancer appears under a microscope. Pathologists evaluate how abnormal the cells look, how actively they are dividing, and how much dead tissue is present within the tumor. Grade 1 tumors are generally less aggressive, while grade 3 tumors tend to grow and spread more quickly.

Stage also considers tumor size, location, nearby lymph nodes, and distant metastases. Sarcomas often spread through the bloodstream, with the lungs being a common destination. Lymph-node involvement is less common in many adult subtypes, although exceptions exist.

Soft Tissue Sarcoma Treatment

Treatment is highly individualized. A plan suitable for a small, low-grade tumor in the forearm may be completely inappropriate for a high-grade retroperitoneal sarcoma or metastatic leiomyosarcoma. Care at a center with a multidisciplinary sarcoma team can help coordinate pathology, surgery, radiation oncology, medical oncology, radiology, rehabilitation, and supportive care.

Surgery

Surgery is the main treatment for many localized soft tissue sarcomas. The goal is to remove the tumor with a margin of healthy tissue around it. Negative surgical margins reduce the likelihood that microscopic cancer cells remain in the area.

Modern limb-sparing surgery allows many tumors in an arm or leg to be removed without amputation. Reconstruction, physical therapy, occupational therapy, or rehabilitation may be necessary to preserve strength and function.

Radiation therapy

Radiation may be delivered before surgery to shrink or sterilize the tumor area, or afterward to reduce the risk of local recurrence. It may also be used when surgery is not possible or to relieve symptoms from advanced disease.

The timing involves trade-offs. Preoperative radiation generally treats a smaller area but may increase short-term wound complications. Postoperative radiation may involve a larger field and can produce more long-term stiffness, swelling, or tissue changes. The care team weighs these considerations for each patient.

Chemotherapy

Chemotherapy is not automatically required for every soft tissue sarcoma. It may be recommended for certain high-risk localized tumors, disease that cannot be removed surgically, metastatic cancer, or subtypes known to be chemotherapy-sensitive.

Doxorubicin has long been a major systemic treatment. Other drugs or combinations may include ifosfamide, dacarbazine, gemcitabine, docetaxel, trabectedin, or eribulin, depending on the subtype and treatment history.

Targeted therapy, immunotherapy, and cell therapy

Molecular testing is increasingly important because some sarcomas carry alterations that can be matched with targeted treatments. Approved options include drugs such as pazopanib for certain previously treated advanced soft tissue sarcomas and imatinib for appropriate gastrointestinal stromal tumors.

Atezolizumab is used for advanced alveolar soft part sarcoma. In 2024, the FDA granted accelerated approval to afamitresgene autoleucel, also called Tecelra, for selected adults with unresectable or metastatic synovial sarcoma. Eligibility requires specific HLA types, tumor expression of the MAGE-A4 antigen, and previous chemotherapy.

This therapy is an example of how sarcoma treatment is moving away from a one-size-fits-all model. The new model is closer to a very complicated lock-and-key collection in which pathology and biomarker testing help identify the right key.

Recurrence and Follow-Up Care

Soft tissue sarcoma can return near the original tumor or in another part of the body. Follow-up commonly includes physical examinations and periodic imaging, with the schedule based on subtype, grade, location, treatment, and recurrence risk.

Visits may be more frequent during the first two or three years after treatment because many recurrences occur during this period. Some subtypes, however, can recur later, making long-term follow-up important.

Survivorship care may also address pain, reduced mobility, lymphedema, fatigue, nerve symptoms, emotional distress, fertility, heart health after certain chemotherapy drugs, and the long-term effects of radiation.

Experiences and Practical Lessons From the Sarcoma Journey

The following discussion reflects common, composite experiences reported across sarcoma care. It does not describe one specific patient and should not replace individualized medical advice.

The diagnosis may begin with an ordinary-looking lump

A common experience begins with someone noticing a lump in a thigh, shoulder, arm, or abdomen. The mass may not hurt, so it is easy to blame it on exercise, an old injury, or a harmless fatty growth. A primary care clinician may reasonably suspect a lipoma because benign lumps are far more common than sarcomas.

The turning point is often continued growth. A person may notice that clothing fits differently or that the lump is becoming firmer. Requesting another examination is not being difficult; it is providing new clinical information. Photographs, measurements, and a timeline can help a clinician understand that the mass is changing.

Waiting for pathology can be emotionally exhausting

The biopsy itself may be brief, but pathology can take time. Sarcoma classification sometimes requires special stains, molecular testing, or review by another specialist. During that interval, people often search the internet and encounter survival figures stripped of context. This is approximately as calming as inviting a raccoon to organize the kitchen.

A more useful strategy is to write down questions and wait for the complete diagnosis. Knowing the exact subtype, grade, tumor size, location, and stage is more valuable than reading a generic statistic about “sarcoma.”

A second opinion may change the plan

Because soft tissue sarcoma is rare, many patients seek pathology or treatment review at a high-volume sarcoma center. This does not necessarily mean the original team made an error. It means rare tumors often benefit from clinicians who see them repeatedly.

An expert team may recommend a different biopsy approach, additional imaging, radiation before surgery instead of afterward, molecular testing, or a specialized operation. Patients can ask whether the case has been reviewed at a multidisciplinary tumor board and how frequently the center treats that particular subtype.

Treatment affects more than the tumor

A successful operation may still produce weakness, numbness, stiffness, altered appearance, or reduced range of motion. Someone treated for a thigh sarcoma may need to relearn stairs. A person with an abdominal tumor may face digestive changes or a lengthy recovery from complex surgery.

Rehabilitation is not an optional decorative ribbon tied around “real” cancer treatment. Physical therapy, occupational therapy, pain management, nutrition support, and mental health care can directly affect independence and quality of life.

Scan anxiety is real

Follow-up scans can create a repeating cycle of worry sometimes called scanxiety. The days before imaging may bring insomnia, irritability, or a sudden belief that every cough is evidence of lung metastasis. Planning the scan and results appointment close together can reduce waiting. Some people also limit online searching, schedule a distracting activity, or bring a trusted person to the results visit.

Caregivers need support, too

Caregivers may coordinate appointments, medications, insurance paperwork, transportation, meals, and emotional support while quietly attempting to maintain their own work and health. They can benefit from specific help rather than vague offers. “Can you drive us Tuesday?” is easier to answer than “Let us know if you need anything.”

Statistics should inform, not define

A survival percentage can help explain why early diagnosis and appropriate treatment matter. It cannot account for every biological or personal detail. Two people with tumors that share a stage may have different subtypes, grades, molecular targets, surgical options, and responses to treatment.

Many people find it more manageable to focus on the next decision: confirming pathology, completing staging, choosing a treatment team, preparing for surgery, managing side effects, or attending the next scan. Cancer care is still a long road, but it becomes less overwhelming when divided into visible stretches rather than treated as one enormous, foggy highway.

Conclusion

Soft tissue sarcoma is rare, diverse, and often difficult to recognize early. Approximately 13,910 cases are expected in the United States in 2026, and outcomes vary greatly according to stage, grade, subtype, tumor location, and treatment.

A new or enlarging lump should be evaluated, especially when it is deep, firm, painful, or growing. Diagnosis requires carefully planned imaging and biopsy, while treatment may involve surgery, radiation, chemotherapy, targeted therapy, immunotherapy, or specialized cell therapy.

The most important takeaway is that “soft tissue sarcoma” is the beginning of the diagnosis, not the complete diagnosis. Expert pathology, accurate staging, and subtype-specific care provide the clearest foundation for making informed decisions.